NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) news coverage focuses on its progress as a clinical-stage life sciences and biopharmaceutical company developing central nervous system therapeutics designed to overcome the blood-brain barrier. News releases frequently highlight updates from Phase 1/2a and Phase 2a clinical trials of intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma and other high-grade gliomas, as well as regulatory and operational milestones across its CNS oncology pipeline.
Investors following NTHI news can expect detailed reports on radiographic response rates, progression-free survival and long-term survival outcomes from NEO100 studies, along with safety and tolerability findings associated with prolonged intranasal dosing. Additional news items describe the advancement of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors, including U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb clinical development.
Company announcements also cover strategic partnerships and corporate developments, such as the establishment of the NuroMENA subsidiary in the United Arab Emirates, a Master Services Agreement with IROS (an M42-affiliated contract research organization), and share exchange or acquisition transactions disclosed in Form 8‑K filings. Updates on non-dilutive NIH STTR funding, intellectual property expansion, and NeOnc’s AI and 3D bioprinting initiatives for sonodynamic therapy research with NEO100 are also common themes.
By monitoring this NTHI news feed, readers can track NeOnc’s clinical data readouts, regulatory interactions, regional expansion efforts and financing-related disclosures as they are released through press announcements and SEC-referenced communications.
NeOnc Technologies Holdings (Nasdaq: NTHI) announced early clinical improvement in its first child treated with investigational NEO100 in Abu Dhabi. Treating physicians reported that the critically ill three-year-old boy with an aggressive brain tumor is breathing without ventilator support and beginning to move his legs after treatment began. These observations involve one patient and do not establish that NEO100 caused the improvement or predict other patients’ outcomes.
The child did not qualify for the NEO100-03 pediatric trial and receives intranasal treatment outside it through NeOnc’s Compassionate Care program, coordinated with physicians and the Department of Health – Abu Dhabi. In June 2026, NeOnc announced local IND authorization across three NEO100 protocols, with the pediatric Phase 1 and Phase 1b pathway pending further protocol review. The authorizations do not constitute commercial approval.
NeOnc Technologies Holdings (NASDAQ: NTHI) appointed Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, to its board. The company is pursuing UAE clinical development alongside its U.S. programs.
Both lead candidates have Abu Dhabi investigational drug authorizations. NEO100’s June authorization covers adult Phase 1–2 protocols; pediatric studies require further protocol review. NEO212 completed Phase 1 dose escalation, with potential Phase 2 development subject to ethics approvals and other pre-enrollment conditions.
August topline results from the 24-patient NEO100 Phase 2a study included six-month progression-free survival of 48.9% and median overall survival of 26.09 months. NeOnc priced a $15 million registered direct offering and redeemed all Series A convertible preferred stock without issuing common shares. A November 17 FDA meeting is scheduled for NEO212; the company expects to discuss potential Phase 2 design and regulatory pathways.
NeOnc Technologies Holdings (NTHI) CEO Amir F. Heshmatpour will speak at the Abu Dhabi Future Health Summit on October 22, 2026. The summit runs October 20–22 at the ADNEC Centre in Abu Dhabi. His panel, “The Investment Lens: Banking on Prediction,” will examine investment in predictive healthcare. He will discuss clinical development financing, international collaboration and biomarker-informed drug development.
The appearance follows UAE clinical development authorizations announced in June 2026 for NEO100 and NEO212. NEO100 authorization covers adult Phase 1, Phase 1b and Phase 2 protocols for progressive or recurrent Grade III or IV gliomas, with pediatric Phase 1 and Phase 1b studies pending further protocol review. NeOnc is also engaging regional stakeholders through its NuroMENA collaboration platform to pursue partnerships supporting its CNS oncology pipeline.
NeOnc Technologies Holdings (NTHI) appointed Ali Alabedin to its Board of Directors effective October 9, 2026, succeeding Dr. Steven L. Giannotta. Giannotta will remain on the Scientific Advisory Board.
NEO212 completed Phase 1 dose escalation and is advancing toward Phase 2. Abu Dhabi granted investigational new drug authorization, subject to ethics approvals and other pre-enrollment conditions; it is not marketing approval or confirmation of enrollment. An FDA End-of-Phase 1 Type B meeting is scheduled for November 17, 2026.
The 24-patient NEO100 Phase 2a study reported six-month progression-free survival, meaning survival without disease worsening, of 48.9% versus a prespecified 20% benchmark, and median overall survival of 26.09 months. NeOnc also redeemed its outstanding Series A convertible preferred stock; the company said this eliminated associated potential dilution without issuing common shares.
NeOnc Technologies Holdings (NTHI) appointed Ali Alabedin to its Board of Directors, effective October 9, 2026, as it advances clinical development. Alabedin heads the Islamic Banking Group at First Abu Dhabi Bank and succeeds Dr. Steven L. Giannotta, who will remain on NeOnc’s Scientific Advisory Board.
The Department of Health – Abu Dhabi granted NEO212 investigational new drug authorization, supporting NeOnc’s planned Phase 2 development in the UAE. Required ethics approvals and other pre-enrollment conditions remain pending.
NeOnc Technologies Holdings (NTHI) reported median overall survival of 26.09 months in its Phase 2a study of intranasal NEO100 for recurrent brain cancer. The 24-patient study enrolled people with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. Survival was measured from the first treatment dose after recurrence; estimated survival was 60.9% at 12 months and 54.1% at 24 months. Adverse events were predominantly low-grade, with no major toxicities reported.
The study had no concurrent control group. Progression-free survival reached statistical significance against a historical benchmark under RANO 2.0 assessment criteria, but not under the original protocol criteria. NeOnc plans FDA discussions on a registrational pathway. Separately, an FDA End-of-Phase 1 meeting for NEO212 is confirmed for November 17, 2026; it does not establish an agreed approval pathway.
NeOnc Technologies Holdings (NASDAQ: NTHI) has scheduled an FDA meeting for its investigational brain-cancer therapy NEO212 on November 17, 2026. The End-of-Phase 1 Type B meeting will address the proposed patient population, trial design, endpoints, dose selection and evidence for a future marketing application. Roth Capital analyst Jonathan Aschoff anticipates an October end-of-Phase 2 FDA meeting for NEO100 and sees pivotal trials potentially starting before year-end.
NEO100's Phase 2a study met its primary endpoint: six-month progression-free survival was 48.9%, versus a prespecified historical benchmark of 20%. Median overall survival was 26.09 months in the open-label, 24-patient study of recurrent or progressive IDH1-mutant high-grade glioma. NEO100 holds FDA Orphan Drug, Fast Track and Rare Pediatric Disease designations. Roth's September 24 Buy initiation followed Buy initiations from Alliance Global Partners, Maxim Group and BTIG.
NeOnc Technologies Holdings (NTHI) is scheduled to meet the FDA on November 17, 2026, about NEO212’s next clinical-development steps.
The End-of-Phase 1 meeting will cover a proposed Phase 2 patient population, trial design, endpoints and dose, and potential paths toward a marketing application. NEO212 completed Phase 1 dose escalation with a recommended Phase 2 dose of 610 mg. Reported tumor reduction of approximately 60% in one glioblastoma patient and approximately 16 months of stable disease in another patient with brain metastasis remain individual observations, not controlled evidence of efficacy. NEO212 also received UAE IND authorization.
For NEO100, Phase 2a six-month progression-free survival was 48.9% versus a prespecified 20% benchmark (p=0.0047). NeOnc completed a $15 million offering at $4.20 per share with warrants, then redeemed 6,000 Series A preferred shares for $6 million in cash.
NeOnc Technologies Holdings (NTHI) is scheduled to discuss NEO212 trial design and dosing with the FDA on November 17, 2026. The End-of-Phase 1 meeting will cover the proposed patient population, endpoints and a possible accelerated-approval pathway. Phase 1 reached a maximum tolerated dose of 810 mg, and the recommended Phase 2 dose is 610 mg. One patient had approximately 60% tumor reduction and 21 months of disease control; individual observations do not establish efficacy.
For NEO100, NeOnc reported six-month progression-free survival of 48.9% against a prespecified 20% benchmark and median overall survival of 26.09 months. Roth Capital initiated coverage with a $20 price target. NeOnc also raised institutional capital in a September offering priced at $4.20 per share with accompanying warrants.
NeOnc Technologies (NTHI) will meet FDA on November 17, 2026, to discuss the next stage of NEO212 development.
The End-of-Phase 1 meeting follows completion of dose escalation in the NEO212-01 Phase 1/2 trial. FDA authorized NeOnc to proceed with the trial’s Phase 2a and 2b portions in September 2025. NeOnc plans to seek feedback on the proposed patient population, trial design, endpoints, dose and evidence needed for a future marketing application. It also intends to discuss whether a proposed design could support accelerated approval; the scheduled meeting does not establish FDA agreement.
Dose escalation stopped after a dose-limiting toxicity at 810 mg; 610 mg was selected as the recommended Phase 2 dose. One patient with recurrent glioblastoma had a partial response, including an approximately 60% reduction in tumor size, followed by disease control lasting 21 treatment months. A patient with lung cancer metastatic to the brain had stable disease for approximately 16 months. These individual outcomes do not establish efficacy and require confirmation in larger studies.